Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

BACKGROUND: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The aim was to evaluate the long-term safety, tolerabil...

Descripción completa

Detalles Bibliográficos
Autores principales: Newsome, Scott D., Scott, Thomas F., Arnold, Douglas L., Nelles, Gereon, Hung, Serena, Cui, Yue, Shang, Shulian, Naylor, Maria L., Kremenchutzky, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113734/
https://www.ncbi.nlm.nih.gov/pubmed/30181778
http://dx.doi.org/10.1177/1756286418791143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113734/
https://www.ncbi.nlm.nih.gov/pubmed/30181778
http://dx.doi.org/10.1177/1756286418791143

Ejemplares similares